Impact of persistent and cleared preformed HLA DSA (cas 138685-19-5) on kidney transplant outcomes

Add time:09/27/2019    Source:sciencedirect.com

Preformed HLA donor-specific antibodies (DSA (cas 138685-19-5)) only detected with Luminex have been associated with increased risk of antibody-mediated rejection (ABMR) and graft failure after kidney transplantation (KT). Their evolution after KT may modify this risk. We analyzed postransplant evolution of preformed DSA identified retrospectively and their impact on outcomes of 370 KT performed 2006–2014. Antibodies were monitored prospectively at 1-3-5 years after KT and if any dysfunction. Early acute ABMR was more frequent among patients with preformed DSA class-I or I + II than isolated class-II (29.4% vs 4.5%, p = 0.02). One year post-KT, 20 of 34 patients with functioning KT had persistent DSA. Preformed DSA class-II persisted more frequently than class-I/I + II (66.7% vs 33.3%; p = 0.031). The only risk factor independently associated with persistence was pretransplant MFI. Patients with de novo DSA had the highest risk of ABMR (HR 22.2 [CI 6.1–81.2]). Although recipients with persisting preformed DSA had significantly increased ABMR risk (HR 14.7 [CI 6.5–33.0]), those with cleared preformed DSA also had a higher risk than those without DSA (HR 7.01 [CI 2.2–21.8]).Preformed DSA are a very important risk factor for ABMR and graft loss. Patients who clear preformed DSA still show an increased risk of ABMR and graft loss after KT.

We also recommend Trading Suppliers and Manufacturers of DSA (cas 138685-19-5). Pls Click Website Link as below: cas 138685-19-5 suppliers

Prev:CLINICAL STUDYEffectiveness of MRA on embolized intracranial aneurysms: a comparison of DSA (cas 138685-19-5), CE-MRA, and TOF-MRA
Next:PaperN,N,N-trimethylsphingosine (cas 138686-73-4) modifies aggregatory response and ATP release from platelets in whole blood)